Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse

2006 ◽  
Vol 210 (1) ◽  
pp. 49-58 ◽  
Author(s):  
R Natrajan ◽  
RD Williams ◽  
SN Hing ◽  
A Mackay ◽  
JS Reis-Filho ◽  
...  
Biostatistics ◽  
2004 ◽  
Vol 6 (1) ◽  
pp. 45-58 ◽  
Author(s):  
P. Wang ◽  
Y. Kim ◽  
J. Pollack ◽  
B. Narasimhan ◽  
R. Tibshirani
Keyword(s):  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 785-785 ◽  
Author(s):  
Ruben Carrasco ◽  
Giovanni Tonon ◽  
Cameron Brennan ◽  
Alexei Protopopov ◽  
Raktim Sinha ◽  
...  

Abstract Multiple Myeloma (MM) is characterized by a clonal proliferation of abnormal plasma cells in the bone marrow and is among the most frequent and lethal hematological diseases. In spite of significant effort towards the identification of the molecular events leading to this malignancy, the genetic alterations responsible for the pathogenesis of this disease remain poorly understood. Regional copy number alterations (CNAs) in cancer genomes have been among the most informative structural changes in cancer and have led to the discovery of many oncogenes and tumor supressor genes. Using array comparative genomic hybridization (array-CGH) and expression microarray technologies we have analyzed a large collection of cell lines and clinically annotated primary tumors. This high-resolution genomic analysis has identified all previously reported regional gains and losses as well as many novel highly recurrent genetic loci with potential biological and clinical relevance. In particular, we have identified an amplification at chromosome 1q21 as one of the most recurrent genetic changes in cell lines and in a subgroup of primary tumors. This chromosomal change has been previously implicated with disease progression. Analysis across several cell lines has allowed the identification of a Minimal Common Region (MCRs) of amplification at 1q21. Correlation between DNA copy number changes and expression profiling data has identified a limited set of candidate genes within this MCR that are amplified and overexpressed. Using shRNAi technology we have identified BCL-9 as a candidate gene residing at the 1q21 MCR. In vitro and in vivo functional data about the role of BL-9 will be presented. These data will provide critical understanding on the diverse pathways leading to Multiple Myeloma progression.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1429-1429
Author(s):  
Claudia Haferlach ◽  
Melanie Zenger ◽  
Vera Grossmann ◽  
Alexander Kohlmann ◽  
Susanne Schnittger ◽  
...  

Abstract Abstract 1429 Background: Besides the immunophenotype, the karyotype is an important prognostic factor in ALL. In contrast to other leukemias, in ALL cytogenetic entities can be defined based on the number of chromosomes as so-called ploidy groups. A small subgroup with low-hypodiploid/near triploid karyotype was described, which seems to be associated with adverse outcome (Charrin et al, Blood 2004), but was poorly characterized so far. Aim: Characterize the subset of ALL with low-hypodiploid/near triploid karyotype with respect to the patterns of chromosomal gains and losses and additional structural abnormalities and prognosis. Patient and Methods: In total, 561 adult ALL patients with cytogenetic analysis at diagnosis were studied (median age: 52.5 yrs, range: 16–90 yrs). All cases were analyzed in addition by interphase FISH for the presence of BCR-ABL1- and MLL-rearrangements. Further, 16 patients (pts) with low-hypodiploidy/near triploidy and 18 pts with normal karyotype were evaluated by array-CGH (Human CGH 12×270K Whole-Genome Tiling Array; Roche NimbleGen, Madison, WI). Results: Near-haploidy (25–29 chromosomes) was observed in 2 (0.3%) and low-hypodiploidy (30–39 chromosomes) in 11 (1.9%) pts. 52 pts (9.3%) showed between 40 and 45 chromosomes and 356 pts (63.5%) 46 chromosomes. In 88 pts (15.7%) the chromosome number was between 47 and 50. 36 patients (6.4%) belonged to the high-hyperdiploid subset (51–65 chromosomes), 6 (1.1%) pts showed near-triploidy (66–79 chromosomes), and 10 (1.8%) near-tetraploidy (84–100 chromosomes). ALL with near-haploid/low-hypodiploid/near-triploid karyotype (n=19): This ALL subtype comprises ALL with near-haploid/low-hypodiploid karyotype (n=13) and ALL with near-triploid karyotype (n=6). A typical pattern of lost chromosomes was observed. Whilst chromosomes 3 and 7 were lost in all pts, chromosomes 1, 5 and 21 were retained in the majority of pts (n=18). 6/13 pts with near-haploidy or low-hypodiploidy showed a subclone with doubling of the aberrant chromosome set. In 6 pts with near-triploid karyotype the pattern of gained and lost chromosomes suggested that this near-triploid clone most probably evolved from the doubling of a near-haploid/low-hypodiploid clone with a comparable pattern of lost and retained chromosomes as observed in ALL with near-haploid/low-hypodiploid karyoytpe. Thus, in total 19/561 (3.4%) showed a low-hypodiploid/near-triploid karyotype with a typical pattern of lost and retained chromosomes. This genetic subgroup occurred only in B-cell precursor ALL (c-ALL and Pro-B-ALL) and showed a median age of 68.8 yrs (range: 15.7–77.9 yrs). In none of these pts a BCR-ABL1- or MLL-rearrangement was present. Structural abnormalities in addition to chromosome losses were found in 11/19 pts by chromosome banding analysis, the only recurrent one was a deletion 9p observed in 2 pts. In 16 of these 19 pts array CGH analyses were performed and revealed cytogenetically cryptic gains (n=9) and losses (n=18) in 11 pts. 13/16 pts showed a 9p21 deletion including the CDKN2A locus (10 pts due to monosomy 9 or cytogenetically visible 9p deletion and 3 due to a small cytogenetically cryptic deletion), this was homozygous in 3 pts. Additional recurrent losses were found in 6p22-6p25 (n=2) and 5q23.3-5q31.1 (n=2). Further, 18 pts (17 B-ALL, 1 T-ALL) with normal karyotype were evaluated by array CGH. 5 of these (27.8%) demonstrated a pattern of gains and losses resembling the pattern observed in the low-hypodiploid/near-triploid ALL cases demonstrating that some pts of this entity escape detection by cytogenetics, most probably due to low proliferation in vitro. Further, we confirmed a short median overall survival of only 6.1 months in this adult cohort of low-hypodiploid/near-triploid ALL. Conclusions: 1. ALL with a low-hypodiploid/near-triploid karyotype is a rare entity accounting for 3.4% of adult ALL. It is observed only in B-lineage ALL and shows a typical pattern of lost and retained chromosomes and no BCR-ABL1- or MLL-rearrangement. 2. The only recurrent abnormalities in addition to loss of whole chromosomes were deletions of 6p22-6p25, 5q23.3-5q31.1, and 9p21 including the CDKN2A locus. 3. Array CGH or interphase FISH with centromere specific probes for chromosomes 1, 3, 5, 7, and 21 allows the identification of this specific entity and may be considered in cases with ALL and normal karyotype. Disclosures: Haferlach: MLL Munich Leukemia Laboratory: Equity Ownership. Zenger:MLL Munich Leukemia Laboratory: Employment. Grossmann:MLL Munich Leukemia Laboratory: Employment. Kohlmann:MLL Munich Leukemia Laboratory: Employment. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.


2011 ◽  
Vol 69 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Isabela Nelly Machado ◽  
Juliana Karina Heinrich ◽  
Ricardo Barini

OBJECTIVE: Holoprosencephaly (HPE) is heterogeneous in pathogenesis, integrating genetic susceptibility with the influence of environmental factors. Submicroscopic aberrations may contribute to the etiology of HPE. Our aim was to report the molecular analysis of 4 fetuses with HPE and normal metaphase karyotype. METHOD: A whole genome BAC-array based Comparative Genomic Hybridization (array CGH) was carried out in fetal blood samples. All potential cytogenetic alterations detected on the arrays were matched against the known copy number variations databases. RESULTS: The array CGH analysis showed copy number gains and losses in all cases. We found a recurrent deletion in 15q14 (clone RP11-23J11) and in 15q22 (clone RP11-537k8) in 2 out 4 cases analyzed. We also observed submicroscopic gain in 6p21 in 3 out of 4 fetuses in nearby clones. All these regions were tested in known databases and no copy number variations have been described for them. CONCLUSION: This is the first report of molecular characterization through a whole genome microarray CGH of fetuses with HPE. Our results may contribute to verify the effectiveness and applicability of the molecular technique of array CGH for prenatal diagnosis purposes, and contributing to the knowledge of the submicroscopic genomic instability characterization of HPE fetuses.


2005 ◽  
Vol 48 (4) ◽  
pp. 507-508
Author(s):  
Rachael Natrajan ◽  
Richard Williams ◽  
Sandra Hing ◽  
Suzanne Little ◽  
Alan Mackay ◽  
...  

2013 ◽  
Vol 70 (11) ◽  
pp. 621-631 ◽  
Author(s):  
Deborah Bartholdi ◽  
Peter Miny

Neue Schlüsseltechnologien führen gegenwärtig zu einem grundlegenden Wandel im klinischen Einsatz genetischer Labordiagnostik. In der Pränataldiagnostik hat die nicht invasive Abklärung von Aneuploidien im mütterliche Blut Fuß gefasst (NIPT) und dieser Ansatz wird in Zukunft auch bei anderen Chromosomenstörungen und Fragestellungen (monogene Erkrankungen) zum Einsatz kommen. Im postnatalen Bereich hat die Microarray Analyse (Array-CGH, molekulare Karyotypisierung) die konventionelle Chromosomenanalyse bei der Abklärung von Kindern mit Fehlbildungen, einer nicht-syndromalen geistigen Behinderung oder Autismusspektrumstörung abgelöst. Die neuen Hochdurchsatzsequenziermethoden erlauben die effiziente Abklärung von genetisch sehr heterogenen Krankheitsbildern wie z. B. Epilepsien, neuromuskuläre Erkrankungen und Schwerhörigkeit, durch Diagnostik-Panels, bei welchen Dutzende von Genen parallel analysiert werden können. Der Einsatz der Exom oder whole genome Sequenzierung als wissenschaftliche Methode zur Identifizierung von neuen Krankheitsgenen wird auch in der Diagnostik von schweren ungeklärten Erkrankungen oder Entwicklungsstörungen, die genetisch extrem heterogen sind, zum Einsatz kommen. Die neuen Methoden werden die klinische Diagnostik in der Pädiatrie und anderen Bereichen der Medizin über kurz oder lang verändern, indem die genetische Labordiagnostik eher früher im Abklärungsprozess zur Anwendung kommen wird (genetics first).


Sign in / Sign up

Export Citation Format

Share Document